Indaptus Therapeutics (INDP) Competitors $2.58 -0.25 (-8.83%) Closing price 09/12/2025 04:00 PM EasternExtended Trading$2.42 -0.17 (-6.40%) As of 09/12/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesSEC FilingsShort InterestTrendsBuy This Stock INDP vs. LPTX, SNGX, EPIX, HOOK, MRKR, GOVX, MBIO, PHXM, SNSE, and ERNAShould you be buying Indaptus Therapeutics stock or one of its competitors? The main competitors of Indaptus Therapeutics include Leap Therapeutics (LPTX), Soligenix (SNGX), ESSA Pharma (EPIX), HOOKIPA Pharma (HOOK), Marker Therapeutics (MRKR), GeoVax Labs (GOVX), Mustang Bio (MBIO), PHAXIAM Therapeutics (PHXM), Sensei Biotherapeutics (SNSE), and Ernexa Therapeutics (ERNA). These companies are all part of the "pharmaceutical products" industry. Indaptus Therapeutics vs. Its Competitors Leap Therapeutics Soligenix ESSA Pharma HOOKIPA Pharma Marker Therapeutics GeoVax Labs Mustang Bio PHAXIAM Therapeutics Sensei Biotherapeutics Ernexa Therapeutics Indaptus Therapeutics (NASDAQ:INDP) and Leap Therapeutics (NASDAQ:LPTX) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, dividends, valuation, profitability, risk, earnings, institutional ownership and media sentiment. Do institutionals & insiders have more ownership in INDP or LPTX? 7.1% of Indaptus Therapeutics shares are owned by institutional investors. Comparatively, 30.5% of Leap Therapeutics shares are owned by institutional investors. 20.8% of Indaptus Therapeutics shares are owned by insiders. Comparatively, 7.5% of Leap Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term. Which has more volatility and risk, INDP or LPTX? Indaptus Therapeutics has a beta of 1.27, suggesting that its share price is 27% more volatile than the S&P 500. Comparatively, Leap Therapeutics has a beta of -0.21, suggesting that its share price is 121% less volatile than the S&P 500. Which has higher earnings and valuation, INDP or LPTX? Leap Therapeutics is trading at a lower price-to-earnings ratio than Indaptus Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioIndaptus TherapeuticsN/AN/A-$15.02M-$37.66-0.07Leap TherapeuticsN/AN/A-$67.56M-$1.58-0.19 Does the media favor INDP or LPTX? In the previous week, Indaptus Therapeutics had 5 more articles in the media than Leap Therapeutics. MarketBeat recorded 6 mentions for Indaptus Therapeutics and 1 mentions for Leap Therapeutics. Leap Therapeutics' average media sentiment score of 1.89 beat Indaptus Therapeutics' score of 0.48 indicating that Leap Therapeutics is being referred to more favorably in the news media. Company Overall Sentiment Indaptus Therapeutics Neutral Leap Therapeutics Very Positive Is INDP or LPTX more profitable? Leap Therapeutics' return on equity of -237.65% beat Indaptus Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Indaptus TherapeuticsN/A -612.59% -243.78% Leap Therapeutics N/A -237.65%-155.38% Do analysts prefer INDP or LPTX? Indaptus Therapeutics presently has a consensus target price of $238.00, indicating a potential upside of 9,124.81%. Leap Therapeutics has a consensus target price of $3.38, indicating a potential upside of 1,030.27%. Given Indaptus Therapeutics' stronger consensus rating and higher possible upside, research analysts clearly believe Indaptus Therapeutics is more favorable than Leap Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Indaptus Therapeutics 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00Leap Therapeutics 0 Sell rating(s) 3 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 SummaryIndaptus Therapeutics beats Leap Therapeutics on 8 of the 13 factors compared between the two stocks. Get Indaptus Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for INDP and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding INDP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart INDP vs. The Competition Export to ExcelMetricIndaptus TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$2.86M$2.59B$5.84B$10.14BDividend YieldN/A56.52%5.68%4.60%P/E Ratio-0.0723.8575.4125.98Price / SalesN/A527.96515.95180.52Price / CashN/A171.1637.5660.44Price / Book0.245.3712.156.29Net Income-$15.02M$32.95M$3.29B$271.07M7 Day Performance-21.82%1.28%0.74%3.87%1 Month Performance-66.97%5.61%5.00%5.49%1 Year Performance-93.90%-1.67%62.55%25.86% Indaptus Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)INDPIndaptus Therapeutics3.3503 of 5 stars$2.58-8.8%$238.00+9,124.8%-93.9%$2.86MN/A-0.076Short Interest ↓High Trading VolumeLPTXLeap Therapeutics2.7317 of 5 stars$0.28-1.2%$3.38+1,095.1%-89.1%$11.70MN/A-0.1840Positive NewsGap DownSNGXSoligenix2.903 of 5 stars$2.68+0.8%$6.00+123.9%-19.1%$11.49MN/A-0.7120Positive NewsShort Interest ↓EPIXESSA Pharma3.0478 of 5 stars$0.24+1.3%$2.00+733.3%-97.0%$11.35MN/A-0.4350Dividend AnnouncementShort Interest ↑HOOKHOOKIPA Pharma3.0847 of 5 stars$0.92+2.2%$4.50+389.3%-81.4%$11.21M$9.35M-0.16160Positive NewsShort Interest ↓Gap DownMRKRMarker Therapeutics3.6656 of 5 stars$0.85-2.7%$13.17+1,447.2%-65.6%$11.01M$6.59M-0.6260Short Interest ↑Gap UpGOVXGeoVax Labs1.7902 of 5 stars$0.69-1.2%$8.50+1,133.7%-75.3%$10.98M$3.95M-0.3410Short Interest ↑MBIOMustang Bio1.0345 of 5 stars$1.47+8.1%N/A-88.3%$10.64MN/A-0.02100Positive NewsShort Interest ↑PHXMPHAXIAM TherapeuticsN/A$3.10flatN/AN/A$10.58MN/A0.0049SNSESensei Biotherapeutics4.7146 of 5 stars$8.25+4.0%$55.00+566.7%-17.4%$10.40MN/A-0.3940Short Interest ↓Gap UpERNAErnexa Therapeutics0.9947 of 5 stars$1.27+2.0%N/A-94.3%$9.70M$580K-0.1510 Related Companies and Tools Related Companies LPTX Alternatives SNGX Alternatives EPIX Alternatives HOOK Alternatives MRKR Alternatives GOVX Alternatives MBIO Alternatives PHXM Alternatives SNSE Alternatives ERNA Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:INDP) was last updated on 9/14/2025 by MarketBeat.com Staff From Our PartnersNvidia Times 1,000,000Nvidia’s latest AI chip is a $25,000 powerhouse — with 80 billion transistors and the ability to perform 60 tr...Paradigm Press | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredApple’s falling behindApple just posted record-breaking results, yet its stock barely moved — because in today’s market, investors o...Porter & Company | Sponsored6-Figure Target for BTC by 2025The U.S. just announced it's putting GDP data directly onto Bitcoin and Ethereum blockchains. Could this spa...Crypto 101 Media | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredEveryone thought he was insane…SpaceX just struck a $17 billion deal with EchoStar for radio frequencies, and tech analyst Jeff Brown says it...Brownstone Research | SponsoredWall Street Legend Issues Urgent AI Stock Warning'Hidden AI' is taking the U.S. stock market by storm.Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Indaptus Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Indaptus Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free INDP Stock Alerts